Market Cap | 15.04K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -5.01M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 17.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 15.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -58.00% |
Recommedations | - | Quick Ratio | 0.17 | Shares Outstanding | 332.08M | 52W Low Chg | 310.00% |
Insider Own | - | ROA | -179.72% | Shares Float | - | Beta | 0.39 |
Inst Own | - | ROE | -726.10% | Shares Shorted/Prior | -/- | Price | 0.04 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 639,001 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 18 | Volume | 205,895 | Change | 2.69% |
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada.